Search

Insmed

Lezárt

SzektorEgészségügy

123.8 0.1

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

122.23

Maximum

125.95

Fő mutatók

By Trading Economics

Bevétel

150M

-13M

Értékesítés

120M

425M

Egy részvényre jutó nyereség

-0.52

Profit margin

-3.112

Munkavállalók

1,664

EBITDA

150M

14M

Ajánlások

By TipRanks

Ajánlások

Erős vétel

12 hónapos előrejelzés

+59.99% upside

Osztalékok

By Acuity

Következő eredményjelentés

2026. okt. 29.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

6.7B

28B

Előző nyitás

123.7

Előző zárás

123.8

Hangulat hírek alapján

By Acuity

64%

36%

303 / 340 Rangsor szerint Healthcare

Insmed Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. aug. 24. 19:56 UTC

Event
Social Media
News

Insmed Inc. received approval for Brinsupri in Japan, the first therapy for non-cystic fibrosis bronchiectasis. Shares are lower amid news of a major shareholder's stock sale.

2026. aug. 20. 20:02 UTC

Insmed Inc shares are lower amid a significant decline in the Biotechnology sector. Trading volume is unusually high, with no specific news identified.

2026. aug. 19. 23:41 UTC

Insmed Inc. shares are higher in after-market trading, reflecting notable volatility with significant fluctuations since Wednesday's close.

2026. aug. 17. 20:02 UTC

Social Media
News

Insmed shares rise as Duquesne Capital reports $151.9 million stake and Mizuho sets a $192 price target amid ongoing product launches.

2026. aug. 14. 19:36 UTC

Insmed Inc shares are lower, reflecting broader market sentiment after a reported decline in retail sales. The stock has closed lower for four consecutive sessions.

2026. aug. 13. 19:51 UTC

News
Social Media

Insmed shares are lower despite raised earnings estimates and target price increases from HC Wainwright and Wells Fargo during Thursday's session.

2026. aug. 12. 19:36 UTC

News

Insmed shares are trading lower despite multiple analysts issuing positive ratings and target price increases, including BMO's $192.00 and Cantor Fitzgerald's $235.00.

2026. aug. 11. 21:16 UTC

Insmed Inc. shares moved slightly lower during after-market hours, remaining near the upper end of their one-month range and above the 20-day moving average.

2026. aug. 10. 23:41 UTC

News

Analysts adjusted price targets for Insmed Inc. after recent evaluations. Shares are higher in after-market trading, reflecting positive sentiment amid these actions.

2026. aug. 7. 21:21 UTC

Insmed Inc shares are lower in after-market hours, with no specific news identified for the decline. The stock remains above its 20-day moving average.

2026. aug. 6. 23:56 UTC

Insmed Inc shares are trading lower in after-market hours. No specific news was identified to explain the decline.

2026. aug. 5. 23:22 UTC

Insmed Inc shares are higher in after-market trading, reflecting positive momentum amid a significant drop in crude oil prices and easing inflation concerns.

2026. aug. 3. 19:16 UTC

Insmed Inc shares are lower today, marking the seventh consecutive session of declines. No specific company news was identified to explain the movement.

2026. júl. 31. 20:06 UTC

Insmed Inc. shares are lower, continuing a seven-session decline amid rising Treasury yields and crude oil prices, with no specific company news identified.

2026. júl. 30. 21:16 UTC

Insmed Inc shares are higher in after-market trading, recovering from earlier losses. The stock rose to a high since Thursday's close.

2026. júl. 28. 19:26 UTC

Insmed Inc shares are lower today, with no specific news identified. Broader market sentiment is bearish, influenced by declines in Asian markets.

2026. júl. 27. 23:41 UTC

Insmed Inc's shares are higher in after-market hours, rebounding from a lower regular session. No specific news was identified for this price movement.

2026. júl. 24. 23:46 UTC

Insmed Inc shares are lower in after-market hours, continuing recent trends. The stock remains near the lower end of its one-month trading range.

2026. júl. 22. 19:11 UTC

Social Media

Insmed shares are lower despite Cantor Fitzgerald's "Overweight" rating and $235 price target, following positive updates on inhalation powder TPIP.

2026. júl. 21. 17:41 UTC

Social Media
News

BMO Capital initiated coverage on Insmed Inc with an Outperform rating and a $192 price target, contributing to the stock's upward movement.

2026. júl. 20. 19:16 UTC

News
Social Media

Insmed Inc's shares are lower today amid declines in the Biotechnology sector. Social media highlights positive sentiment around TPIP data and its strong pipeline.

Társak összehasonlítása

Árváltozás

Insmed Előrejelzés

Célár

By TipRanks

59.99% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 201.22 USD  59.99%

Magas 243 USD

Alacsony 169 USD

19 Wall Street elemző 12 hónapos célárain alapulva a(z)Insmed termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

19 ratings

19

Vétel

0

Tartás

0

Eladás

Hangulat

By Acuity

303 / 340 Rangsor szerint Egészségügy

Hangulat hírek alapján

Bearish bizonyíték

Volatilitás

Átlag alatti

Hírmennyiség (RCV)

Átlag feletti

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Insmed

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
help-icon Live chat